A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Apremilast in Subjects With Active Psoriatic Arthritis
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Apremilast (Primary)
- Indications Psoriatic arthritis
- Focus Biomarker; Therapeutic Use
- Sponsors Celgene Corporation
- 12 Jun 2012 Results published in Arthritis and Rheumatism.
- 05 Nov 2011 Results presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
- 28 May 2011 Patient-reported outcomes results presented at the 12th Annual Congress of the European League Against Rheumatism.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History